financial analysis omega pharma
DESCRIPTION
This a financial analysis of the firm Omega Pharma, in this slidecast you can find the turnover, current and solvency rate , ... of the past 3 years.TRANSCRIPT
![Page 1: Financial analysis Omega Pharma](https://reader031.vdocument.in/reader031/viewer/2022020105/54c2f3ad4a7959357d8b457a/html5/thumbnails/1.jpg)
Lotte Vanmaele2 AF 4
Omega Pharma - Financial analysis
![Page 2: Financial analysis Omega Pharma](https://reader031.vdocument.in/reader031/viewer/2022020105/54c2f3ad4a7959357d8b457a/html5/thumbnails/2.jpg)
Index
•Omega Pharma
•Top brands
•Financial analysis
•Omega Pharma on the stockmarket
•Conclusion
![Page 3: Financial analysis Omega Pharma](https://reader031.vdocument.in/reader031/viewer/2022020105/54c2f3ad4a7959357d8b457a/html5/thumbnails/3.jpg)
Omega Pharma?
• Belgian Pharmaceutical Company
• Foundation: 1987 (By Marc Coucke, Yvan Vindevogel)
• Headquarter: Nazareth, Belgium
• Employees: 2.000
• Operations: 35 countries
• Euronext Brussels & BEL20 Index
• PLC
![Page 4: Financial analysis Omega Pharma](https://reader031.vdocument.in/reader031/viewer/2022020105/54c2f3ad4a7959357d8b457a/html5/thumbnails/4.jpg)
Top brands 2010
Sales: 27 m.
Sales: 33 m. Sales: 12 m.
Sales: 18 m.
![Page 5: Financial analysis Omega Pharma](https://reader031.vdocument.in/reader031/viewer/2022020105/54c2f3ad4a7959357d8b457a/html5/thumbnails/5.jpg)
Financial Analysis
![Page 6: Financial analysis Omega Pharma](https://reader031.vdocument.in/reader031/viewer/2022020105/54c2f3ad4a7959357d8b457a/html5/thumbnails/6.jpg)
Financial Analysis
![Page 7: Financial analysis Omega Pharma](https://reader031.vdocument.in/reader031/viewer/2022020105/54c2f3ad4a7959357d8b457a/html5/thumbnails/7.jpg)
Financial Analysis
2007 2008 2009
-5,000,000
0
5,000,000
10,000,000
15,000,000
20,000,000
Omega Pharma
TurnoverOperating loss, profit
Financial year
Valu
es
in €
![Page 8: Financial analysis Omega Pharma](https://reader031.vdocument.in/reader031/viewer/2022020105/54c2f3ad4a7959357d8b457a/html5/thumbnails/8.jpg)
Financial Analysis
SHORT OVERVIEW OF THE FIRST QUARTERS IN 2009 AND 2010
Quarter 1 (2010) Quarter 2 (2009) Growth %
Turnover 423,5 411,2 +3%
Operational costs 165,7 156,3 +6%
Net operating profit 33,6 39,0 -14%
Net operating earnings per share
1,44 1,67 -14%
Average number of shares 23.347.309 23.347.309 0%
Values expressed in million €
![Page 9: Financial analysis Omega Pharma](https://reader031.vdocument.in/reader031/viewer/2022020105/54c2f3ad4a7959357d8b457a/html5/thumbnails/9.jpg)
Financial Analysis
PERFORMANCE BY REGION: TURNOVER
Quarter 1 (2010) Quarter 1 (2009) Growth %
West Europe 175,8 174,9 +1%
Belgium 124,6 112,0 +11%
Growth markets (East Eur. & Turkey) 46,4 41,0 +13%
France 76,7 83,3 -8%
GROUP 423,5 411,2 +3%
Values expressed in million €
![Page 10: Financial analysis Omega Pharma](https://reader031.vdocument.in/reader031/viewer/2022020105/54c2f3ad4a7959357d8b457a/html5/thumbnails/10.jpg)
Financial Analysis - Geographical breakdown
EBITDA: : Earnings Before Interest, Taxes, Depreciation, Amortization
Emerging markets
13%
West-Eu-rope40%
Belgium28%
France19%
Turnover by region
![Page 11: Financial analysis Omega Pharma](https://reader031.vdocument.in/reader031/viewer/2022020105/54c2f3ad4a7959357d8b457a/html5/thumbnails/11.jpg)
Omega Pharma on the stockmarket
Share price evolution 1998-2010
![Page 12: Financial analysis Omega Pharma](https://reader031.vdocument.in/reader031/viewer/2022020105/54c2f3ad4a7959357d8b457a/html5/thumbnails/12.jpg)
Conclusion
•Strong company
•Large name reputation
•Strong product brands
•Sell in 35 countries
•Share prices
![Page 13: Financial analysis Omega Pharma](https://reader031.vdocument.in/reader031/viewer/2022020105/54c2f3ad4a7959357d8b457a/html5/thumbnails/13.jpg)
THE END
Thank you for watching this slidecast
Lotte Vanmaele
![Page 14: Financial analysis Omega Pharma](https://reader031.vdocument.in/reader031/viewer/2022020105/54c2f3ad4a7959357d8b457a/html5/thumbnails/14.jpg)
Sources
www.omega-pharma.be
www.nbb.be
www.wikipedia.nl